[Cognitive impairment in children with organic asthenic disorder].

Autor:	Chutko LS; N. Bekhtereva Institute of Human Brain Russian Academy of Sciences, St. Petersburg, Russia., Surushkina SY; N. Bekhtereva Institute of Human Brain Russian Academy of Sciences, St. Petersburg, Russia., Yakovenko EA; N. Bekhtereva Institute of Human Brain Russian Academy of Sciences, St. Petersburg, Russia., Anisimova TI; N. Bekhtereva Institute of Human Brain Russian Academy of Sciences, St. Petersburg, Russia., Cherednichenko DV; N. Bekhtereva Institute of Human Brain Russian Academy of Sciences, St. Petersburg, Russia., Didur MD; N. Bekhtereva Institute of Human Brain Russian Academy of Sciences, St. Petersburg, Russia., Chekalova SA; Research Institute of Hygiene and Health of Children and Adolescents Federal State Autonomous Institution «NMIC for Children's Health», Moscow, Russia.
Jazyk:	ruština
Zdroj:	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2023; Vol. 123 (9. Vyp. 2), pp. 92-99.
DOI:	10.17116/jnevro202312309292
Abstrakt:	Objective: To study cognitive impairment and neurophysiological characteristics in children with organic asthenia, as well as the effectiveness of the drug Cogitum in the treatment of this pathology. Material and Methods: The main study group included 40 children aged 8 to 10 years with a diagnosis of «Organic asthenic disorder» (F06.6). The control group consisted of 30 children aged 8 to 10 years without manifestations of asthenia. The following research methods were used in the work: the asthenic state scale (ASS) by L.D. Malkova to assess the severity of asthenic syndrome, the S. Lee «SCT» (sluggish cognitive tempo) scale to assess manifestations of low cognitive tempo, the «Random Access Memory» method to quantify working memory, the TOVA (The Test of Variables of Attention) computer test to quantify assessment of attention disorders and impulsivity level, electroencephalogram (routine and spectral analysis) ( p <0.05). For the treatment of patients from the study group, the drug Cogitum was used at a dose of 10 ml of a drinking solution per day for 30 days. Results: In was shown that children from the study group were characterized by a decrease in working memory (7.8±2.9 vs 14.9±5.4), a statistically significant increase in SCT scores ( p <0.05), a significantly greater degree of inattention and impulsivity with a tendency to an increase in the number of errors in the second half of the TOVA test ( p <0.05). Comparative analysis of EEG relative power data showed a statistically significant increase in the power of waves in the alpha and theta ranges in the fronto-central leads of both hemispheres in the group of children with organic asthenic disorder ( p <0.05). When re-evaluating the condition of children after treatment, a statistically significant decrease in the manifestations of asthenia on the ASS scale was recorded in 77.5% of cases. At the same time, there was a significant improvement in attention, memory, and indicators characterizing a low cognitive pace. The results of an electroencephalographic study after a course of treatment showed a decrease in the relative power of the EEG in the theta and alpha ranges in the anterior sections of the cerebral cortex ( p <0.05), which indicates an increase in the level of activation of neocortical structures. Conclusion: Thus, the use of the drug Cogitum for the treatment of organic asthenic disorder leads not only to a decrease in asthenia and cognitive impairment, but also to an improvement in the functional state of the brain.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu